Stockreport
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity [Yahoo! Finance]
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations: corbuspharma.com
Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly 3% at 14 days in individuals with obesity CRB-913 is a non-incretin daily oral small molecule with the potential to deliver a therapeutic option for weight loss and long-term weight management NORWOOD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced the last patient has been enrolled and completed the first clinical visit (Last Patient First Visit) in the Company's CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is on track to be completed in the summer of 2026. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management. The CANYON-1 Phase 1b clinical trial is a 16-week, double-blind, placeb
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | CRBP | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
CRBP alerts
CRBP alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
NEWS
NEWS
- Mizuho Sees Strong Risk-Reward in Corbus Pharmaceuticals Holdings, Inc. (CRBP) Near Cash Value [Yahoo! Finance][Yahoo! Finance]
- Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity[GlobeNewswire]
- Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer[GlobeNewswire]
- Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit[GlobeNewswire]
- How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33% [Yahoo! Finance][Yahoo! Finance]
- More
CRBP
SEC Filings
SEC Filings
- 4/16/26 - Form DEFA14A
- 4/16/26 - Form 8-K
- 4/14/26 - Form 8-K
- CRBP's page on the SEC website
- More